Is Remdesivir-Maker Gilead Sciences a 'Buy'?


It said it was building a consortium of manufacturing partners to maximise global supply of the drug, which requires scarce raw materials and special manufacturing capabilities with limited global capacity.

This is the first step to develop the active pharmaceutical ingredient in a drug.

Last Friday, the US Food and Drug Administration authorized its emergency use for coronavirus patients in serious condition.

'Any disruption to the supply chain impacting these scarce raw materials and other manufacturing inputs could reduce the amount of remdesivir produced and increase the time it takes to do so'.

"The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery", Anthony Fauci, the top USA epidemiologist who oversaw the study, told reporters on Friday.

With no other approved treatments for Covid-19, interest in the drug is growing around the world.

World leaders launch $ 8B initiative, United States says no
He warned that the African continent was "extremely vulnerable to the ravages of this virus and is in need of support". We can not allow that to happen", he added. "And we will come out of it stronger, together", he said.

Additionally, the company is in "advanced discussions" with the United Nations' UNICEF, explain, about how to provide medicine to low- and middle-income nations.

Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing worldwide clinical trials but its safety and efficacy for the treatment of COVID-19 are not yet established.

Japan has approved the use of the experimental anti-viral drug remdesivir, for the treatment of coronavirus patients with severe symptoms.

A study of 1,063 patients, some of whom received a placebo, in hospitals around the world showed that the drug shortened the recovery time by 31 percent - from 15 to 11 days, the BBC reports. The trial found no significant difference in mortality rates.

Remdesivir was previously available only for patients enrolled in clinical trials or those cleared to get the drug under expanded use and compassionate use programmes. This has already been authorised by the Spanish Medicines and Health Products Agency.